AlphaVax, Inc. (AVX) is a privately-held specialty biopharmaceutical company focused on the development of vaccines for the treatment and management of various cancers. AVX is based in Research Triangle Park, North Carolina.

AVX uses its proprietary alphavaccine VRP technology, which has been validated in a number of human clinical studies, to create new, potentially first-in-class vaccines that engage the body’s immune system to both recognize and fight off various cancers.

AlphaVax has a number of product candidates in various stages of development for the treatment of melanoma, colon cancer and breast cancer. Certain data to date clearly suggests that our vaccines have a demonstrable benefit in overall patient survival in advanced colon cancer patients, for example.

• Successfully completed the manufacture, testing and release of AVX901, a HER2-VRP vaccine for a Phase I study in advanced and metastatic breast cancer in which patient enrollment will begin in 2Q, 2012 at the Duke University Medical Center.
• Executed an exclusive license with the US Department of Defense, Office of Chemical-Biological Medical Systems (CBMS) to the alphavaccine platform for the development of Marburg and Ebola vaccines. This license enables the Department of Defense to develop these vaccines in return for payments related to licensing and technology transfer.
• In June, 2011, the Board of Directors of the Company was expanded to seven directors. The new members bring significant experience in managing and growing pharmaceutical and biotechnology companies.
• In January, 2012, the Company completed an amended agreement with Novartis Vaccines and Diagnostics in which certain obligations of both companies were re-defined. AlphaVax also benefited through the receipt of payments related to technology transfer.
• Relocation of the Company’s manufacturing operations to its corporate headquarters in Research Triangle Park, NC, is underway, thereby improving efficiency and reducing expense.